Open-label continuation treatment study with levodopa - carbidopa intestinal gel in subjects with advanced Parkinson's disease and severe motor-fluctuations who have exhibited a persistent and positive effect to treatment in previous studies

Trial Profile

Open-label continuation treatment study with levodopa - carbidopa intestinal gel in subjects with advanced Parkinson's disease and severe motor-fluctuations who have exhibited a persistent and positive effect to treatment in previous studies

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 29 Apr 2016 Primary endpoint changed from 'continued access to LCIG treatment' to 'Adverse Events', hence trial focus changed from TU to AR
    • 09 Oct 2015 Planned primary completion date changed from 1 May 2015 to 1 Sep 2020, as reported by ClinicalTrials.gov.
    • 20 Oct 2014 Planned End Date changed from 1 May 2015 to 1 Sep 2020 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top